Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and ...

Canadian health authorities cleared the firm's application to study ANS01 as treatment for advanced solid tumor patients harboring various MET alterations.

The decision reaffirming the FDA's oversight authority over cell and gene therapy products was praised by the International ...

Four US cancer centers are partnering with leading technology firms to analyze cancer patient data while maintaining privacy and regulatory compliance.

With help from the oversubscribed financing round, the Australian firm is eyeing early 2025 for a Phase I clinical trial of its TAG-72-targeting cell therapy.

Researchers explored whether the uptake of pre-test education and cancer risk genetic testing was similar for patients who used a chatbot or met with a genetic counselor.

The radiopharmaceutical, already approved for SSRT-expressing GEP-NETs, may be a new option in meningioma if future research ...

Patients had fewer bleeds after treatment with Beqvez compared to standard treatment, but questions remain about which ...

The firm sees potential for AI algorithms to support drug development by screening patients for biomarkers and predicting their responses to cancer therapies.

The firm will use the funding to begin a first-in-human trial of its autologous macrophage cell therapy in liver disease.

The firm said it will discuss biomarker results, including a marked decrease in N-acetylaspartate levels and an increase in brain white matter.

Prevail will buy $350,000 worth of shares in Hemogenyx and will serve as a contract research organization for an upcoming clinical trial in pediatric leukemia.